

March 5, 2020 B. Braun Medical Inc. Tracy Larish Sr. Regulatory Affairs Specialist 901 Marcon Blvd. Allentown, Pennsylvania 18109

Re: K193101

Trade/Device Name: Omnifix Low Dead Space Luer Lock Syringe

Regulation Number: 21 CFR 880.5860 Regulation Name: Piston Syringe

Regulatory Class: Class II Product Code: FMF Dated: January 21, 2020 Received: February 3, 2020

### Dear Tracy Larish:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <a href="https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products">https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products</a>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems">https://www.fda.gov/medical-device-problems</a>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</a>) and CDRH Learn (<a href="https://www.fda.gov/training-and-continuing-education/cdrh-learn">https://www.fda.gov/training-and-continuing-education/cdrh-learn</a>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</a>) for more information or contact DICE by email (<a href="DICE@fda.hhs.gov">DICE@fda.hhs.gov</a>) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

For CAPT Alan Stevens
Assistant Director
DHT3C: Division of Drug Delivery and
General Hospital Devices,
and Human Factors
OHT3: Office of Gastrorenal, ObGyn,
General Hospital and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

**Enclosure** 

# DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

# **Indications for Use**

510(k) Number (if known)

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020

See PRA Statement below.

K193101		
Device Name Omnifix® Low Dead Space Luer Lock Syringe		
Indications for Use (Describe)		
The B.Braun Omnifix® Low Dead Space Luer Lock Syringes are intended to be used to inject fluid into, or withdraw fluids from the body.		
Type of Use (Select one or both, as applicable)		
Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)		
CONTINUE ON A SEPARATE PAGE IF NEEDED.		

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

### 5. 510(k) SUMMARY

# **SUBMITTER INFORMATION:**

Name: B. Braun Medical Inc.
Address: 901 Marcon Boulevard

Allentown, PA 18109-9341

**Telephone Number:** 610-266-0500, ext. 2966

Contact Person: Tracy Larish, Sr. Regulatory Affairs Specialist

**Telephone Number:** (610) 596-2941 **Fax Number:** (610) 849-9286

Email: tracy.larish@bbraunusa.com

**Date Prepared:** November 8<sup>th</sup>, 2019

#### **DEVICE NAME:**

Device Trade Name: Omnifix® Low Dead Space Luer Lock Syringes

Common Name: Piston Syringes

Classification Name: Piston Syringe, 21 CFR §880.5860: Class II, Product code

**FMF** 

#### PREDICATE DEVICES:

• K071459 B. Braun Omnifix® Piston Syringes

#### **DEVICE DESCRIPTION**

The Omnifix® Low Dead Space (LDS) Luer Lock Syringes consist of a graduated hollow barrel and a movable plunger (piston) with a plunger tip. One end of the barrel has a male connector (nozzle), which permits attachment to a female connector (hub) and a needle. The luer lock nozzle has a centric configuration. The Omnifix ® Low Dead Space (LDS) syringes will be available in 1 mL and 2 mL.

# **INDICATIONS FOR USE:**

The B. Braun Omnifix® Low Dead Space Luer Lock syringes are intended to be used to inject fluid into, or withdraw fluids from, the body.

# **TECHNOLOGICAL CHARACTERISTICS:**

The proposed Omnifix® Low Dead Space Luer Lock Syringe is substantially equivalent to the predicate Omnifix® Piston Syringes in terms of indications for use, intended use, general design, functional performance and materials of construction.

The difference between the proposed Omnifix® Low Dead Space Luer Lock Syringe and the predicate do not raise new issues of safety and effectiveness.

	Proposed Device:Omnifix® Low Dead	Predicate Device: Omnifix® piston syringes
	Space (LDS) Luer Lock Syringes	(K071459)
Indications	The B.Braun Omnifix® Low Dead Space Luer	B. Braun Omnifix® Piston Syringes: The B. Braun
	Lock Syringes are intended to be used to inject	Omnifix® Piston Syringes are intended to be used to
	fluid into, or withdraw fluids from the body.	inject fluid into, or withdraw fluids from, the body.
	Single use only, disposable	Single use only, disposable
Material	Syringe barrel: Polypropylene	Syringe barrel: Polypropylene
Composition	Syringe plunger:Polypropylene or Polystyrene	Syringe plunger: Polystyrene or Polypropylene
	Plunger tip(piston) Polyisoprene	Plunger tip (piston): Polyisoprene
	Lubricant: Silicone fluid	Lubricant: Silicone fluid
Sizes	1 mL, 2 mL	1 mL,2 mL,2.5 mL,3 mL,5 mL,10 mL,20 mL,30 mL, &
		50 mL
Syringe tip	Centric tip, luer lock	Syringe tip configurations: centric and eccentric tips,
configurations		luer slip and luer lock versions (syringes of < 5 mL
		centric only)
Markings	Graduated scale markings meet requirements	Graduated scale markings meet requirements of ISO
	of ISO 7886-1:2017	7886-1:1993 and ISO 8537:1991 (E)
Maximum low	$\leq 0.023$ mL or 67% less than ISO 7886-1:2017	Meets ISO 7886-1:2017
dead space	requirement	
volume		
specification		
Barrel	translucent	translucent
transparency:		
Sterilization	Ethylene Oxide	Ethylene Oxide

#### NONCLINICAL TESTING

Bench testing performed on Omnifix® Low Dead Space Luer Lock Syringe demonstrates that the device performs as intended and supports substantial equivalence of the proposed device. No clinical testing was performed as this device does not require clinical studies to demonstrate substantial equivalence with the predicate device. The following testing has been successfully completed for the proposed devices:

- o Biocompatibility in accordance with ISO 10993-1:2018
- o Sterilization Residual testing in accordance with ISO 10993-7:2008
- o Sterilization Validation in accordance with ISO 11135:2014
- Testing in accordance with ISO 7886-1:2017, ISO 80369-7:2016 and ISO 80369-20:2015
- o Performance and functional testing to internal specifications

#### **CONCLUSION:**

Results of the functional and performance testing conducted on the proposed devices demonstrate that the Omnifix® Low Dead Space Luer Lock Syringes are as safe and effective as the predicate devices. The differences, between proposed devices and predicate devices, do not raise any new issues of safety and effectiveness. Therefore, proposed Omnifix® Low Dead Space Luer Lock Syringe are substantially equivalent to the predicate devices.